Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07645209 | A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions | active not recruiting | — | 1,000 | Harbin Medical UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 1 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Jun 11, 2026 |
| clinicaltrials |
| NCT06204159 | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery(Trinav) | active not recruiting | N/A | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer(DUET-BTC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06778317 | mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis(SEPT9_SuRV) | recruiting | — | 400 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06986785 | A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 74 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07116486 | A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07145801 | Y-90 Treatment Response Using Transarterial Radioembolization(TARE) | recruiting | Phase 2 | 30 | Thomas Jefferson UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07351669 | A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma | recruiting | — | 121 | Zhongda HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07417800 | Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning | recruiting | — | 11,000 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639801 | 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors | not yet recruiting | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07640048 | Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study | recruiting | — | 90 | Peking Union Medical College HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06900543 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere(CHEERS) | active not recruiting | Phase 3 | 108 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07466225 | HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion | active not recruiting | — | 150 | Peking UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT00451022 | Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | recruiting | — | 750 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07628751 | A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC(SOCRATES HCC) | recruiting | N/A | 218 | University Health Network, TorontoOTHER | 2 | Jun 5, 2026 | clinicaltrials |
| NCT07629193 | Liver Transplant for Hepatocellular Carcinoma(TH-CHC) | not yet recruiting | — | 562 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07630610 | Feasibility and Safety of Augmented Reality (AR) in Liver Tumor Surgery | not yet recruiting | N/A | 6 | Navari Surgical ABINDUSTRY | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07587216 | Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment | recruiting | — | 800 | Tongji HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07444905 | Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma | active not recruiting | — | 1,523 | Tongji HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623265 | Improving the Use of Immunotherapy to Treat Liver Cancer(IO-MARC) | recruiting | N/A | 300 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02379377 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | active not recruiting | Phase 1 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03823144 | Intravital Microscopy in Human Solid Tumors | recruiting | N/A | 85 | Mayo ClinicOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03257761 | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | active not recruiting | Phase 1 | 55 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05507632 | Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 48 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07618546 | A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors | not yet recruiting | N/A | 208 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 1, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07614061 | Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer | recruiting | Phase 1 | 18 | Shanghai Zhongshan HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT07483359 | Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus(CONV3RSION) | recruiting | Phase 2 | 38 | First Hospital of China Medical UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610551 | Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma | recruiting | — | 50 | Air Force Military Medical University, ChinaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06544083 | Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood | recruiting | — | 600 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07495579 | Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)(REVIVE) | not yet recruiting | Phase 2 | 146 | Asan Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04982653 | Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy | recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05620771 | Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | recruiting | Phase 2 | 200 | Northwestern UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03896646 | Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) | active not recruiting | N/A | 42 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04196465 | Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(NeoChance) | active not recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07493668 | Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy(FLEX-HCC) | recruiting | Phase 2 | 80 | CHA UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07594340 | HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) | recruiting | Phase 3 | 300 | Binkui LiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602504 | China Metastatic Liver Cancer Clinical Registry Cohort Database | recruiting | — | 2,000 | Anhui Provincial HospitalOTHER_GOV | 1 | May 22, 2026 | clinicaltrials |
| NCT05546879 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC(Liver-NET1) | active not recruiting | Phase 1 | 43 | University Hospital, GrenobleOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07581730 | A Subharmonic-Aided Pressure Estimate Technology for Prediction of Response to Systemic Therapy in Gastric Cancer Liver Metastases | not yet recruiting | — | 107 | The First Hospital of Jilin UniversityOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07587034 | HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 315 | Shanghai Zhongshan HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07600346 | A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery | not yet recruiting | — | 105 | The First Hospital of Jilin UniversityOTHER | 0 | May 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 12, 2026source: clinicaltrials